BGM Stock Price & Analysis — Qilian International Holding Group Limited (Healthcare >> Drug Manufacturers - Specialty & Generic)
BGM FAQ
What is BGM's P/E ratio?
Qilian International Holding Group Limited (BGM) currently trades at a P/E ratio of 115.85.
What is BGM's ROE?
Qilian International Holding Group Limited reports a Return on Equity (ROE) of -5.10%.
What is BGM's dividend yield?
Qilian International Holding Group Limited offers a dividend yield of 0.00%.
What is BGM's Quality Score?
Our AI rates BGM's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy BGM?
Our AI Timing Score for BGM is 0 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does BGM belong to?
Qilian International Holding Group Limited is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange
BGM AI Analysis Summary
Our AI summary for BGM: Qilian International Holding Group Limited (NASDAQ), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of 115.85, ROE of -5.10%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 0/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 0.30
Price
-0.01
(-2.01%)
Day Change
|
|
|---|
BGM, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/E ratio is relatively high
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
41% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.30 |
| PBV / Sector |
0.10 / 10.19
GREAT
|
| Earning Per Share | -0.18 |
| PE / Sector |
115.85 / 31.74
|
| PEG or PE/Growth / Sector |
N/A / -0.02
|
| Average 1M Daily Value |
0.02 M
GREAT
|
| Average 1W Daily Value |
0.01 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
52% |
| Return to Investors |
|
37% |
| Registration Details |
| Analyze Date | 2026-08-06 07:59:42 |
| Symbol | BGM |
| Name | QILIAN INTERNATIONAL HOLDING GROUP LIMITED |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NASDAQ |
| Listed Shares | 380.62 M |
| Par Value | N/A |
| Calculated From | YearEnd |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 38.09 / 10,556.24 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: No. 152 Hongliang East 1st Street, Chengdu, China, 610200
Phone: 86 28 6477 5180
Website: https://www.bgmgroupltd.com
Employees: 298
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. It offers oxytetracycline products, including Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline active pharmaceutical ingredients, which are used by pharmaceutical companies in the manufacturing of medications that use oxytetracycline as an active ingredient. The company also provides licorice products, such as Gan Di Xin, a medicine made from raw licorice materials; Qilian Shan licorice extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, an ingredient for medical preparation companies to produce compound licorice oral solutions. In addition, it offers traditional Chinese medicine derivatives products comprising Ahan antibacterial paste that is used to treat refractory chronic skin diseases; heparin products, including heparin sodium preparation, an ingredient for pharmaceutical companies to produce medications used in treating cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and sausage casings, such as Zhu Xiaochang sausage casings for culinary purposes. Further, the company provides Fertilizer products comprising Xiongguan organic fertilizers to improve crop yield, increase soil's chemical properties, and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers for plant growth. Additionally, it focuses on the AI-driven commercialization of DuXiaoBao platform. BGM Group Ltd. is based in Chengdu, China.
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › Drug Manufacturers - Specialty & GenericAnalysed on the same criteria, ordered by market cap
Google